Do SARMs like S-23 suppress natural testosterone production, and how significant is that suppression?

Yes — S-23 suppresses natural testosterone by reducing LH and FSH output from the pituitary via androgen receptor activation in the hypothalamic-pituitary axis. Suppression magnitude is dose- and duration-dependent. At 10–20 mg/day over four to six weeks, serum testosterone can fall substantially below baseline. Bloodwork at cycle end is the only reliable way to quantify how deep suppression has gone before choosing a recovery protocol.

When is a mini-PCT sufficient after an S-23 cycle, and what does it involve?

A mini-PCT is generally adequate after short, lower-dose S-23 runs where post-cycle bloodwork confirms LH and FSH remain detectable rather than fully suppressed. In practice this means a three-to-four week SERM course — typically nolvadex at 20 mg/day — is sufficient to stimulate gonadotropin recovery. Longer or higher-dose cycles may require an extended protocol; bloodwork, not a fixed calendar, should determine when recovery is complete.

Which bloodwork markers should I check to assess HPTA suppression from S-23?

The primary markers are serum LH, FSH, and total testosterone. These three values together reveal whether the pituitary is still signalling the testes and whether the testes are responding. SHBG may also shift during and after a cycle. Ideally, baseline labs are drawn before the first tablet, mid-cycle labs around week three or four, and end-of-cycle labs before starting any recovery protocol.

How should S-23 10mg tablets be dosed throughout the day for stable blood levels?

S-23 has an estimated half-life of approximately twelve hours in research models, so splitting the daily dose into two equal administrations — morning and evening — maintains more consistent plasma concentrations than a single daily dose. For a 20 mg/day protocol, that means one tablet in the morning and one in the evening, each taken with a small meal to support absorption.

How should the S-23 blister pack be stored to maintain tablet potency over a full cycle?

Store the blister pack at room temperature (15–25 °C), away from direct light and humidity. Individual blister cells protect each tablet until point of use, so do not pre-pop tablets into an open container. Keep the pack sealed until each dose is taken. If stored correctly, tablet integrity is maintained through the printed expiry date without refrigeration. (2) angle_used

Pharma Grade

Master Pharma

S-23 SARM 10mg/tab 60 Tablets by Master Pharma

Name: S-23 SARM
Brand: Master Pharma
SKU: SARM-S23-MAS-002
Price: 65.00 EUR
Availability: InStock

S-23 is a third-generation nonsteroidal SARM that binds androgen receptors with high affinity, making HPTA suppression management — and the adequacy of a lighter post-cycle protocol — the central clinical consideration for research applications. Each tablet delivers a precisely pressed 10 mg dose of S-23, with 60 tablets per blister pack offering a full investigational cycle. Every production batch clears dual-gate analytical release: HPLC active-content verification and LAL endotoxin quantification, both documented lot-specifically on the Certificate of Analysis.

€65.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers consistent 10 mg S-23 per tablet for predictable suppression-curve research
Blister-cell packaging isolates each dose until point of use, preventing moisture degradation
Lot-specific HPLC CoA enables researchers to cross-reference active content against dosing logs
60-tablet count covers a full four-to-six week investigational cycle without reordering
LAL endotoxin testing on every batch confirms pyrogen control for oral research applications
Pharma-grade tablet pressing ensures uniform disintegration and reproducible absorption patterns

Phase	Dosage	Note
Low-suppression exploration	10 mg/day (1 tablet, single dose or split)	Use to establish individual suppression baseline; run bloodwork at week 3 to quantify LH/FSH change
Standard investigational cycle	20 mg/day (2 tablets, split AM/PM)	Supports meaningful anabolic signal research; expect measurable HPTA suppression — plan recovery protocol before cycle starts
Mini-PCT (post short/low-dose cycle)	Nolvadex 20 mg/day for 3–4 weeks	Applicable only when post-cycle bloodwork confirms detectable residual LH/FSH; extend if recovery markers lag
Full recovery protocol (post longer cycle)	Nolvadex 20–40 mg/day for 4–6 weeks	Required when LH and FSH are fully suppressed at cycle end; re-test bloodwork at protocol completion

Key takeaways

Monitor LH, FSH, and total testosterone before starting any S-23 cycle.
Calibrate your recovery protocol to bloodwork results, not fixed calendar weeks.
Split the daily S-23 dose twice daily to maintain stable plasma concentrations.
Confirm HPLC active-content via the lot-specific Certificate of Analysis supplied.
Reserve mini-PCT only for short, low-dose cycles with confirmed partial suppression.

S-23 and HPTA Suppression: What Separates It From Milder SARMs

S-23 produces measurable suppression of endogenous testosterone through dose-dependent inhibition of LH and FSH secretion — the defining pharmacological feature that shapes every responsible research protocol built around this compound. Unlike ostarine or MK-677, which exert comparatively modest effects on the hypothalamic-pituitary-gonadal axis, S-23 demonstrates suppression profiles in preclinical models that more closely resemble moderate androgen exposure. Serum LH and FSH are the primary bloodwork markers that quantify this suppression; researchers monitoring these values alongside total testosterone can detect axis changes within two to four weeks of administration.

How Suppression Depth Determines Recovery Strategy

The adequacy of a lighter post-cycle protocol depends directly on verified suppression depth rather than compound identity alone. A short S-23 run at lower investigational doses — typically 10–15 mg per day for four to six weeks — may produce recoverable suppression that responds to a mini-PCT anchored by a selective estrogen receptor modulator (SERM) such as nolvadex for three to four weeks. Longer cycles or higher doses push suppression deeper, requiring a more structured recovery window and potentially extending the SERM phase. Compared to recovery timelines following full AAS cycles, even suppression-heavier SARM protocols typically restore baseline LH and FSH faster due to the absence of esterified androgens with prolonged clearance times.

Analytical Release and Tablet Integrity

Master Pharma releases each S-23 10 mg batch against a specific HPLC method calibrated to S-23's chromatographic profile, confirming active content against a traceable reference standard — not an estimate derived from a pooled batch result. LAL endotoxin testing accompanies every lot. S-23 tablets carry measurable bioavailability, and dose consistency per tablet directly affects the suppression pattern a researcher observes; a batch with active-content variance introduces unpredictability into the HPTA response being studied. The lot-specific Certificate of Analysis dispatched with each order closes that variable.

Semantic Anchors

S-23 suppresses LH and FSH secretion through dose-dependent androgen receptor activation at the hypothalamic level.
HPLC verification confirms active content against a traceable reference standard for every production lot.
A mini-PCT protocol addresses recoverable suppression by using a SERM to stimulate endogenous gonadotropin release.

Usage

Run a full baseline bloodwork panel — LH, FSH, total testosterone, SHBG — at least 48 hours before the first dose to establish suppression reference values.
Begin at 10 mg/day (one tablet) for the first week to assess individual tolerance before advancing to the target investigational dose.
Split daily doses across morning and evening administrations to align with S-23's estimated 12-hour half-life and reduce peak-to-trough plasma fluctuation.
Take each tablet with a small meal; consistent food timing improves absorption reproducibility across the cycle.
Repeat bloodwork at week 3–4 of the cycle to quantify LH, FSH, and testosterone suppression; use those results to pre-select the appropriate recovery protocol.
Begin the chosen recovery protocol — mini-PCT or full PCT — within 24–48 hours of the final tablet, timed to S-23's clearance window; do not begin recovery before bloodwork confirms cycle end.

Warnings

Contraindications: Not indicated for use in individuals under 21 years of age, those with pre-existing hypogonadism, or anyone with a documented history of androgen-sensitive conditions. Women of childbearing potential should not use this compound due to androgenic activity in preclinical reproductive studies.

Side Effects: Dose-dependent testosterone suppression is the primary expected effect and should be treated as a certainty rather than a risk. Additional reported effects in research contexts include decreased HDL cholesterol, mood variability during suppression, and potential vision disturbances at higher doses. Lipid panels should be monitored alongside hormonal markers.

Monitoring: Minimum monitoring framework: LH, FSH, total testosterone, and lipid panel at baseline, mid-cycle, and post-cycle. Any LH or FSH reading at or near zero at mid-cycle warrants dose review or early cycle termination followed by a structured recovery protocol.

PCT: A SERM-based recovery protocol is mandatory following any S-23 cycle. Mini-PCT (nolvadex 20 mg/day, 3–4 weeks) is appropriate only for short, low-dose cycles where mid-cycle bloodwork shows partial rather than full gonadotropin suppression. Full PCT with extended SERM duration applies to all other scenarios. Do not rely on time-off alone as a recovery strategy.

Frequently asked questions

Do SARMs like S-23 suppress natural testosterone production, and how significant is that suppression?: Yes — S-23 suppresses natural testosterone by reducing LH and FSH output from the pituitary via androgen receptor activation in the hypothalamic-pituitary axis. Suppression magnitude is dose- and duration-dependent. At 10–20 mg/day over four to six weeks, serum testosterone can fall substantially below baseline. Bloodwork at cycle end is the only reliable way to quantify how deep suppression has gone before choosing a recovery protocol.
When is a mini-PCT sufficient after an S-23 cycle, and what does it involve?: A mini-PCT is generally adequate after short, lower-dose S-23 runs where post-cycle bloodwork confirms LH and FSH remain detectable rather than fully suppressed. In practice this means a three-to-four week SERM course — typically nolvadex at 20 mg/day — is sufficient to stimulate gonadotropin recovery. Longer or higher-dose cycles may require an extended protocol; bloodwork, not a fixed calendar, should determine when recovery is complete.
Which bloodwork markers should I check to assess HPTA suppression from S-23?: The primary markers are serum LH, FSH, and total testosterone. These three values together reveal whether the pituitary is still signalling the testes and whether the testes are responding. SHBG may also shift during and after a cycle. Ideally, baseline labs are drawn before the first tablet, mid-cycle labs around week three or four, and end-of-cycle labs before starting any recovery protocol.
How should S-23 10mg tablets be dosed throughout the day for stable blood levels?: S-23 has an estimated half-life of approximately twelve hours in research models, so splitting the daily dose into two equal administrations — morning and evening — maintains more consistent plasma concentrations than a single daily dose. For a 20 mg/day protocol, that means one tablet in the morning and one in the evening, each taken with a small meal to support absorption.
How should the S-23 blister pack be stored to maintain tablet potency over a full cycle?: Store the blister pack at room temperature (15–25 °C), away from direct light and humidity. Individual blister cells protect each tablet until point of use, so do not pre-pop tablets into an open container. Keep the pack sealed until each dose is taken. If stored correctly, tablet integrity is maintained through the printed expiry date without refrigeration. (2) angle_used

Manufacturer

S-23 sits within Master Pharma's oral SARM line — a segment the brand developed with a formulation-first approach: analytical acceptance limits for each active ingredient are defined at the SKU level during development, so the release specification a batch must meet was written specifically for that molecule's physicochemical profile, not adapted from a generic tablet template. For the S-23 10 mg SKU, this means the HPLC method accounts for S-23's chromatographic behaviour specifically, with reference standard selection and column chemistry chosen accordingly. What this specialisation delivers to the end researcher is straightforward: the active-content figure on the lot-specific Certificate of Analysis is a result generated by a method built for this compound — not a cross-applied method carried over from a different SARM SKU. LAL endotoxin quantification is applied to every oral batch as a manufacturing control standard, consistent with the brand's injectable-line protocols. Master Pharma's compound-level analytical focus is the operational expression of its specialisation principle.

Product details

Brand	Master Pharma
Active ingredient	s-23
Also known as	s-23, S-23 SARM, Master Pharma s-23
Strength	10 mg
Form	Tabletten
Pack size	60 pieces
Item number	SARM-S23-MAS-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

S-23 10mg/tab 30 Tablets by Vital Research

S-23 is a non-steroidal selective androgen receptor modulator (SARM) that binds androgen receptors in skeletal muscle and bone with tissue-specific affinity, producing anabolic signalling without the broad hormonal disruption characteristic of classic anabolic-androgenic steroids. Each tablet delivers a precisely measured 10 mg of S-23 API, with 30 tablets per blister pack. Quality is verified at the lot level: HPLC quantifies active-compound content and LAL endotoxin assay confirms microbiological safety before release.

€48.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00